ALX Oncology Holdings Inc. - Common Stock (ALXO)

The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Discover the stocks with unexpected trading volume in today's session on the US markets.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

ALX Oncology reports Q2 2025 results with a net loss of $25.9M, wider than expected, but shares dip only slightly. Clinical progress, including evorpacept data and ALX2004 trials, remains key focus. Cash reserves extend runway to Q1 2027.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

ALXO stock results show that ALX Oncology Holdings beat analyst estimates for earnings per share the second quarter of 2024.